Falsely prolonged prothrombin time test in a patient with erythrocytosis: a case report.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
26 Jan 2024
26 Jan 2024
Historique:
medline:
2
2
2024
pubmed:
2
2
2024
entrez:
2
2
2024
Statut:
aheadofprint
Résumé
The prothrombin time (PT) test is commonly used to monitor deficiencies in coagulation factors. A prolonged PT may indicate a deficiency of factors II, V, VII, X, and fibrinogen, or the presence of an inhibitor. However, further tests are required to differentiate between a true factor deficiency and the presence of an inhibitor. It is important to note that falsely prolonged PT can lead to misdiagnosis and inappropriate clinical intervention that can have life-threatening consequences. A 19-year-old woman with elevated hematocrit levels and prolonged PT was diagnosed with secondary erythrocytosis due to cyanotic congenital heart disease with ventricular septal defect (VSD). However, further investigation revealed that the prolonged PT result was false. Excess citrate in the blood sample, caused by polycythemia, led to this misleading outcome, resulting in unnecessary and potentially harmful treatment. This incident emphasizes the importance of laboratory personnel and clinicians being aware of the test's limitations. Not only should specialists in thrombosis and hemostasis possess this knowledge, but it is also pertinent for general laboratory staff, as well as laboratory directors and specialists. The significance of accurate laboratory testing for the proper diagnosis and treatment of patients is highlighted in this case.
Identifiants
pubmed: 38305118
doi: 10.1097/MBC.0000000000001276
pii: 00001721-990000000-00125
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of prothrombin time/international normalized ratio (PT/INR). Int J Lab Hematol 2021; 43:21–28.
Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med 2014; 34:453–477.
Sehgal T, Nanda A, Prakash S, Subramanian A. Use of modified-citrate tube to rectify spurious coagulopathy in smoker's polycythaemia: medical resolution of a dentist's dilemma. BMJ Case Rep 2022; 15:e246102.
Hu ZD, Gu B, Deng AM. A dyspnea patient with abnormal prolonged prothrombin time and activated partial thromboplstin time, but without bleeding symptoms. J Thorac Dis 2012; 4:235–237.
Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007; 82:864–873.
Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10:222.
Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013; 347:f6667.
Austin M, Ferrell C, Reyes M. Do elevated hematocrits prolong the PT/aPTT? Clin Lab Sci 2013; 26:89–94.
Marlar RA, Potts RM, Marlar AA. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values. Am J Clin Pathol 2006; 126:400–405.
Nguyen E, Harnois M, Busque L, et al. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Blood Cancer J 2021; 11:75.
Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. British Committee for Standards in Haematology Guidelines on the management of massive blood loss. Br J Haematol 2006; 135:634–641.
Mladěnka P, Macáková K, Kujovská Krčmová L, et al. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev 2022; 80:677–698.
Maguire M, Fuh L, Goldstein JN, et al. Thromboembolic risk of 4-factor prothrombin complex concentrate versus fresh frozen plasma for urgent warfarin reversal in the emergency department. West J Emerg Med 2019; 20:619–625.
Luo Y, Ma C, Yu Y. Application of fresh frozen plasma transfusion in the management of excessive warfarin-associated anticoagulation. Blood Sci 2022; 4:57–64.